Key terms

About QURE

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest QURE news

Apr 08 10:20pm ET Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR) Mar 25 1:55pm ET Cantor Fitzgerald biotech analyst holds an analyst/industry conference call Mar 25 4:55am ET Cantor Fitzgerald biotech analyst holds an analyst/industry conference call Mar 21 11:28am ET Cantor Fitzgerald biotech analyst holds an analyst/industry conference call Mar 04 6:43am ET uniQure price target lowered to $7 from $10 at Mizuho Mar 01 12:05pm ET Positive Outlook for uniQure Backed by Strong Gene Therapy Pipeline and Strategic Advancements Mar 01 11:59am ET uniQure price target lowered to $25 from $30 at H.C. Wainwright Mar 01 1:01am ET Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), uniQure (QURE) and RegenXBio (RGNX) Feb 29 9:51am ET Snowflake downgraded and upgraded: Wall Street’s top analyst calls Feb 29 8:55am ET Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties Feb 29 8:52am ET Goldman downgrades uniQure on uncertain path in Huntington’s Feb 29 8:48am ET uniQure downgraded to Neutral from Buy at Goldman Sachs Feb 29 7:22am ET RBC Capital Remains a Buy on uniQure (QURE) Feb 29 5:43am ET Maintaining Hold on uniQure Amid Regulatory Uncertainty and Financial Considerations Feb 29 1:02am ET A New Cause for Concern: uniQure N.V. Adds a New Innovation / R&D Risk Feb 28 12:45pm ET Buy Rating Affirmed for uniQure: Promising Gene Therapy Pipeline and Solid Financial Outlook Feb 28 10:20am ET Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), uniQure (QURE) Feb 28 7:12am ET uniQure reports FY23 EPS ($6.47), consensus ($6.31) Jan 22 1:45pm ET Buy Rating Affirmed on uniQure’s Advancing Gene Therapy Pipeline and Anticipated Regulatory Progress Jan 15 8:47pm ET RBC Capital Reaffirms Their Buy Rating on uniQure (QURE) Jan 12 5:53am ET Maintaining Hold on uniQure Amid Regulatory Uncertainty and Prudent Financial Strategy Jan 11 1:58am ET Hold Rating on uniQure Amidst FDA Approval Discussions for AMT-130 Gene Therapy

No recent news articles are available for QURE

No recent press releases are available for QURE

QURE Financials

1-year income & revenue

Key terms

QURE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

QURE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms